A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Inclusion Criteria:

• Female participants ≥18 years of age, at screening who are overtly healthy asdetermined by medical evaluation including medical history, physical examination,laboratory tests, and cardiac monitoring.

• BMI of 16 to 32 kg/m2; and a total body weight >50 kg (110 lb).

• Participants who are willing and able to comply with all scheduled visits, treatmentplan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine,pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, orallergic disease (including drug allergies, but excluding untreated, asymptomatic,seasonal allergies at the time of dosing).

• Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).

• History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV,Hepatitis B surface antigen (HBsAg), Antibody to hepatitis B surface antigen (HBsAb), Hepatitis B core antibody (HBcAb), or Hepatitis C Virus Antibody (HCVAb). Apositive HBsAb result and a history of Hepatitis B vaccination is allowed.

• History of thromboembolic diseases.

• History of bleeding tendencies.

• History of myocardial infarction, unstable angina, arterial revascularization,mechanical prosthetic heart valve, stroke, New York Association Functional ClassII-IV heart failure, or transient ischemic attack.

• Any known allergy or intolerance to midazolam or other drugs in the benzodiazepineclass, and/or to dabigatran etexilate, and/or to OCs.

• Any medical or psychiatric condition including any active suicidal ideation in thepast year or suicidal behavior in the past 5 years or laboratory abnormality orother conditions that may increase the risk of study participation or, in theinvestigator's judgment, make the participant inappropriate for the study.

• Use of certain prescription or nonprescription drugs and dietary (e.g. grapefruit)and herbal supplements within up to 14 days or 5 half-lives, whichever is longer,prior to the first dose of study intervention.

• Recent exposure to live or attenuated vaccines within 28 days of the screeningvisit.

• History of alcohol abuse or repeated binge drinking and/or any other illicit druguse or dependence within 6 months of screening.

• Use of tobacco/nicotine containing products in excess of the equivalent of 5cigarettes/day or 2 chews of tobacco/day.